Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 3,350 Shares

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 3,350 shares of the company’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $6.32, for a total value of $21,172.00. Following the completion of the transaction, the insider directly owned 795,824 shares in the company, valued at approximately $5,029,607.68. The trade was a 0.42% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Wednesday, December 24th, Chidozie Ugwumba sold 1,490 shares of Clene stock. The stock was sold at an average price of $6.27, for a total transaction of $9,342.30.
• On Monday, December 22nd, Chidozie Ugwumba sold 4,367 shares of Clene stock. The shares were sold at an average price of $6.54, for a total value of $28,560.18.
• On Friday, December 19th, Chidozie Ugwumba sold 5,582 shares of Clene stock. The stock was sold at an average price of $6.45, for a total transaction of $36,003.90.
• On Wednesday, December 3rd, Chidozie Ugwumba sold 56,577 shares of Clene stock. The shares were sold at an average price of $7.86, for a total transaction of $444,695.22.
• On Thursday, December 18th, Chidozie Ugwumba sold 5,816 shares of Clene stock. The shares were sold at an average price of $6.33, for a total transaction of $36,815.28.
• On Wednesday, December 17th, Chidozie Ugwumba sold 2,884 shares of Clene stock. The stock was sold at an average price of $6.61, for a total transaction of $19,063.24.
• On Tuesday, December 16th, Chidozie Ugwumba sold 7,030 shares of Clene stock. The shares were sold at an average price of $6.31, for a total transaction of $44,359.30.
• On Monday, December 15th, Chidozie Ugwumba sold 10,580 shares of Clene stock. The stock was sold at an average price of $6.49, for a total transaction of $68,664.20.
• On Friday, December 12th, Chidozie Ugwumba sold 7,603 shares of Clene stock. The shares were sold at an average price of $6.79, for a total value of $51,624.37.
• On Thursday, December 11th, Chidozie Ugwumba sold 10,907 shares of Clene stock. The stock was sold at an average price of $6.81, for a total value of $74,276.67.

Clene Trading Up 1.2%

Clene stock traded up $0.07 during mid-day trading on Tuesday, hitting $5.96. The stock had a trading volume of 52,752 shares, compared to its average volume of 311,304. The stock has a 50-day simple moving average of $8.20 and a two-hundred day simple moving average of $6.34. The stock has a market capitalization of $61.57 million, a PE ratio of -1.76 and a beta of 0.79. Clene Inc. has a 12 month low of $2.28 and a 12 month high of $13.50.

Clene (NASDAQ:CLNN) last issued its earnings results on Thursday, November 13th. The company reported ($0.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.25). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. Sell-side analysts expect that Clene Inc. will post -5.19 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on CLNN shares. D. Boral Capital reaffirmed a “buy” rating and set a $23.00 price objective on shares of Clene in a research report on Wednesday, December 10th. Benchmark reaffirmed a “buy” rating on shares of Clene in a research report on Thursday, December 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Clene in a research note on Tuesday, October 14th. Finally, UBS Group reiterated a “buy” rating on shares of Clene in a report on Wednesday, December 3rd. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $32.60.

Institutional Trading of Clene

Institutional investors and hedge funds have recently made changes to their positions in the company. Lunt Capital Management Inc. lifted its stake in Clene by 71.2% in the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock valued at $199,000 after purchasing an additional 21,217 shares during the last quarter. Scoggin Management LP raised its holdings in shares of Clene by 75.1% in the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after acquiring an additional 107,250 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Clene during the 2nd quarter valued at about $47,000. Finally, Jones Financial Companies Lllp bought a new position in shares of Clene in the third quarter worth approximately $29,000. Institutional investors own 23.28% of the company’s stock.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).